PLUR Pluri Inc.: Price-to-Projected Revenue Ratio

Pluri - graphic logo of issuer PLUR

Pluri Inc. is recognized as an authoritative developer of cell-based therapies for severe ischemic pathologies. The forward P/S dynamics for Pluri Inc. on the GURU.Markets chart demonstrate a pivot driven by the creation of 3D platforms for regenerative medicine and contracts with US government agencies regarding radiation protection. The current level of 11.50 sets the magnitude of the metric, determining the issuer's degree of market maturity.

Pluristem Therapeutics - PLUR Market Cap to Expected Sales Ratio (period 04/28/2023 - 11/13/2026)

Summary analytical data breakdowns for pluri-biotech.com (PLUR)

- market price and analyst price targets:
Price Chart Pluri|PLUR - Average Forecast Price
- company stock capitalization data:
Market Value PLUR|PLUR - Total Company Value
- book value of equity indicators:
Book Value per Share Pluri|PLUR - Book Valuation of Business|Market Value to Book Value Ratio pluri-biotech.com|PLUR - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity Pluri Inc.|PLUR - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Pluri|PLUR - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio PLUR|PLUR - Company Long-Term Debt|Company Current Liabilities Pluri|Quick Liquidity pluri-biotech.com
- financial results and valuation multiples details:
PLUR - Final Profit|Projected Future Earnings Pluri Inc.|PLUR - Business Payback Period|Projected Price to Earnings Pluri|PLUR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple PLUR|PLUR - Operating income before deduction of amortization|Earnings per share for the last twelve months Pluri|PLUR - Earnings per share for the last 12 months|Quarterly EPS earnings growth pluri-biotech.com|PLUR - Net earnings per share growth this year|Expected earnings per share growth for next year Pluri Inc.
- sales volume and revenue indicators:
PLUR - Company Gross Revenue|Company Projected Revenue Pluri|PLUR - Price-to-Sales Ratio|Price-to-Projected Revenue Ratio PLUR
Fundamental valuation:PLUR (Pluri Inc)
Original product of Pluri

High-tech cell therapy production in Israel with autonomous power supply forms the foundation for scaling revenue at Pluri Inc. This forward P/S indicator compares the current market value of the business with projected sales volume, allowing investors to assess the degree of asset overheating and determine a fair balance between the share price and the fundamental potential for revenue growth.

Who Pluri Inc. competes with

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Price-to-Projected Revenue Ratio Amicus Therapeutics FOLD|ETNB (89bio.com) - Future Price to Revenue|AGIO - Price-to-Projected Revenue Ratio|GPCR: Price-to-Projected Revenue Ratio|MDXG (MiMedx Group) - Forward Price-to-Revenue Multiple|Rezolute Bio (RZLT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Lexicon Pharmaceuticals|MBX: Forward Price to Sales|Forward P/S Multiple ALT|Market Cap to Expected Sales Ratio Aardvark Therapeutics Inc.|Sagimet - Forward Price-to-Revenue Multiple|Forward Price to Sales BIOA|Biomea Fusion, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Quince Therapeutics QNCX|Fractyl Health (GUTS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue VTVT|ATPC (Agape ATP Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Synlogic Corp (SYBX)|Forward Price-to-Revenue Multiple LPCN (Lipocine Inc.)|Market Cap to Expected Sales Ratio matinasbiopharma.com|Price-to-Projected Revenue Ratio Spruce Biosciences, Inc. SPRB|GLTO (Galecto Inc) - Future Price to Revenue|CTCX - Price-to-Projected Revenue Ratio|LUMO: Price-to-Projected Revenue Ratio|ONVO (Organovo Holdings, Inc.) - Forward Price-to-Revenue Multiple|radiuspharm.com (RDUS) - Forward P/S Multiple